Sai Life Sciences to double Process R&D capacity with new Hyderabad facility

Aman Shukla — Mon, 27 Oct 2025 10:15:58 +0000

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO), has announced the groundbreaking of its new CMC Process R&D Center at the company’s integrated R&D campus in Hyderabad. The upcoming facility, scheduled for completion by September 2026, will significantly enhance Sai Life’s R&D infrastructure by doubling its existing Process R&D capacity and introducing advanced capabilities in peptide development, oligo intermediates and linkers, formulation development, and early-phase clinical supplies.

Spread across 100,000 sq. ft. and five floors, the new center is designed as a green building with state-of-the-art laboratories, including a centralized analytical lab, peptide and oligo intermediate facilities, a kilo lab for early clinical manufacturing, and NCE formulation development capabilities. It will operate under containment levels down to OEL 4 (1 µg/m³), ensuring high safety and compliance standards.

The CMC Process R&D Center represents a strategic investment in innovation, scale, and sustainability. It will support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) models, enabling Sai Life Sciences to collaborate flexibly with global innovators across the entire drug development lifecycle—from early-stage research to late-stage CMC programs. This initiative aligns with the company’s broader capital expenditure plans, driven by strong global demand for scalable, high-quality, and partnership-driven drug development solutions.

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma launch Integrated CMC Partnership to accelerate drug development

Aditya Bhagchandani — Wed, 08 Oct 2025 07:25:39 +0000

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE) has announced a strategic collaboration with Agility Life Sciences and Centrix Pharma Solutions to form an Integrated CMC Partnership, designed to accelerate drug development for global innovator biopharma companies.

The partnership combines Sai Life Sciences’ expertise in API development, Agility’s capabilities in formulation development, and Centrix’s strengths in drug product development and clinical manufacturing. Together, the three firms will provide end-to-end Chemistry, Manufacturing, and Controls (CMC) services, enabling clients to move efficiently from preclinical studies to first-in-human (FIH) trials.

According to the company, the alliance offers unified expertise across the CMC value chain, reducing duplication, cost, and time while enhancing coordination and risk management. Clients will benefit from integrated development plans, a single point of contact for project execution, and faster progression from molecule discovery to medicine delivery.

Krishna Kanumuri, MD & CEO of Sai Life Sciences, stated:

“By bringing together our complementary strengths, we can deliver far greater value to innovators—helping them translate ideas into medicines with speed, quality, and efficiency. This partnership reflects our shared commitment to supporting customers from discovery to clinic and ultimately to patients.”

About the Partners:

Sai Life Sciences is a global CRDMO serving over 300 pharma and biotech innovators, with facilities in India, the UK, and the US.
Agility Life Sciences is a UK-based formulation development CDMO recognized for its “Fast Futureproof Formulations” approach.
Centrix Pharma Solutions specializes in drug product development and clinical manufacturing with a patient-centric, science-driven focus.

Disclaimer: The above information is based on Sai Life Sciences’ official filing with BSE and NSE under SEBI (LODR) Regulation 30 dated October 8, 2025.

Sai Life Sciences | Business Upturn

Sai Life Sciences to double Process R&D capacity with new Hyderabad facility

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma launch Integrated CMC Partnership to accelerate drug development